# A method to incorporate prior information into score test for genetic association studies

- Sergii Zakharov
^{1, 2}Email author, - Garrett HK Teoh
^{1}, - Agus Salim
^{3}and - Anbupalam Thalamuthu
^{4}Email author

**15**:24

**DOI: **10.1186/1471-2105-15-24

© Zakharov et al.; licensee BioMed Central Ltd. 2014

**Received: **3 July 2012

**Accepted: **17 January 2014

**Published: **22 January 2014

## Abstract

### Background

The interest of the scientific community in investigating the impact of rare variants on complex traits has stimulated the development of novel statistical methodologies for association studies. The fact that many of the recently proposed methods for association studies suffer from low power to identify a genetic association motivates the incorporation of prior knowledge into statistical tests.

### Results

In this article we propose a methodology to incorporate prior information into the region-based score test. Within our framework prior information is used to partition variants within a region into several groups, following which asymptotically independent group statistics are constructed and then combined into a global test statistic. Under the null hypothesis the distribution of our test statistic has lower degrees of freedom compared with those of the region-based score statistic. Theoretical power comparison, population genetics simulations and results from analysis of the GAW17 sequencing data set suggest that under some scenarios our method may perform as well as or outperform the score test and other competing methods.

### Conclusions

An approach which uses prior information to improve the power of the region-based score test is proposed. Theoretical power comparison, population genetics simulations and the results of GAW17 data analysis showed that for some scenarios power of our method is on the level with or higher than those of the score test and other methods.

### Keywords

Prior information Association analysis Score test Rare variants## Background

In spite of the success of genome-wide association studies (GWAS) in identifying hundreds of common single nucleotide polymorphisms (SNPs) associated with diseases and complex traits (http://www.genome.gov/gwastudies/), in many cases the proportion of heritability explained by these discovered SNPs is low [1–3]. One of the potential explanations of this observation is that rare variants (usually defined as those with minor allele frequency below 1%), which are absent from conventional GWAS studies, are responsible for the missing heritability. Indeed, there is strong evidence that rare variants are associated with some complex traits [4–8].

When performing rare variants association analysis researchers face significant methodological challenges. The single SNP approach, which is popular in GWA studies, is underpowered when applied in rare variants association studies with moderate sample size due to low allele count for each individual rare variant. To overcome this problem, testing multiple rare variants within a region has been recommended [9, 10], and a number of region-based rare variants tests have been proposed [11–15]. However, these novel methodologies may still be underpowered for association studies with moderate sample size [16]. This motivates the development of statistical methods that utilize prior information with the purpose of improving power. Currently, much biological information is publicly available, such as the prediction of degree of deleteriousness of non-synonymous variants (PolyPhen http://genetics.bwh.harvard.edu/pph2/, SIFT http://sift.bii.a-star.edu.sg/), SNP prioritization (FastSNP http://fastsnp.ibms.sinica.edu.tw), functional SNP annotation (SNPnexus http://www.snp-nexus.org/) etc. Although several methods that use prior information have been proposed [17–20], further research is needed to utilize prior knowledge more efficiently [21] and to expand statistical tools available for researchers.

In this article we propose a method that incorporates prior information into the region-based score test. Within our framework, prior information is used to partition SNPs within a genomic region of interest into groups. Then within each group asymptotically independent SNP scores are combined into a one degree of freedom (d.f.) chi-squared statistics. These group statistics are then used to construct a global test for a region. The proposed methodology has several distinct advantages. First of all, the degrees of freedom of our test statistic equals to the number of groups, which may be much less than the number of SNPs within a region. Secondly, under partitioning that approximately separates associated variants from neutral ones (“informative” partitioning) the proposed method efficiently handles noise introduced by neutral variants. We have evaluated the performance of our method on theoretical power comparison, population genetics simulations and analysis of the GAW17 (http://www.gaworkshop.org/gaw17/) real sequencing data set. The results showed that under some scenarios the proposed methodology performed as well as or outperformed the score test and other competing methods.

## Results

### Theoretical power comparison

*L*=10, the number of groups in a partitioning

*K*=2, the range of values for the non-centrality parameter (NCP)

*r*0–30 (x-axis), and the number of variants in a causal group

*L*

_{1}=2,4,6,8 (different values of

*L*

_{1}correspond to different curves). As can be seen, the power gain of the proposed method reached as high as 15 percent when the number of SNPs in the causal group

*L*

_{1}was not large. However, the power of the proposed test was lower than those of the score test when

*L*

_{1}was large. This can be explained from the formula (3), which implies that with an increase in the number of variants in a causal group

*L*

_{1}and fixed NCP

*r*the value of the group statistic

*H*

_{1}monotonically decreases. Also, it is noticeable that with an increase in NCP

*r*up to some point the power difference also increased when

*L*

_{1}was small, whereas the power difference decreased for large values of

*L*

_{1}. For very large values of NCP

*r*the power difference became close to 0 as theoretical powers of both tests tended to 1. Similar conclusions can be obtained from Panel 2 of Figure 1 which shows the results for the scenario with the following parameters:

*L*=100,

*K*=10, varying NCP

*r*(x-axis), and varying

*L*

_{1}=10,20,30,40.

To investigate the impact of the number of groups *K* on power the following model was considered (Panel 3 of Figure 1): *L*=50, *L*_{1}=5, and *K*=8,16,24,32. As can be seen, the power difference is below zero for large values of *K* and above zero for small values of *K*. This may be explained by the fact that the test statistic *T*_{1} (4) is distributed as chi-squared random variable with *K* d.f. Thus, for the fixed NCP *r* and increasing value of *K* the power of the proposed method monotonically decreases.

Alongside the models considered above, it is important to include a scenario when causal variants are split between several groups. Panel 4 of Figure 1 depicts the power difference under the following model: *L* = 54, *K* = 6, and the number of causal groups *m* = 2,3,4,5. Also, for simplicity of presentation it was assumed that each group contained equal number of variants (54/6 = 9), and NCP *r* was split equally between all causal groups. For this scenario the calculation of theoretical distribution of *T*_{1} (4) was done using 500,000 simulations of test statistics under the alternative hypothesis, as equation (6) cannot be used here. As can be seen from Panel 4 of Figure 1, our methodology could gain power if associated SNPs were split between several groups. When the number of causal groups became large, our method was slightly worse than the score test. It should be noted that for all models the maximum power gain of our method (and equivalently the maximum power loss) was achieved when the power of the score test was around 50%. Conclusions similar to those above can be derived from Additional file 1 which shows the same scenarios for the fixed type-1 error rate set at the genome-wide level assuming 35,000 genes (*α* = 0.05/35000).

### Population genetics simulations results

Using population genetics simulations we compared our method with the score test and other proposed approaches, namely, weighted selective collapsing strategy (WSCS) [22], variable threshold (VT) [18], weighted sum of squared scores test (SSUw) [23], and optimal sequence kernel association test (SKAT-O) with linear kernel and beta weights [24]. Since these tests utilize only genotype and phenotype information, we applied our method with MAF (minor allele frequency) partitioning: variants within a region are divided into two groups, namely, those with observed MAF above and below 1%. To estimate the empirical type-1 error we ran the analysis of simulated data under the null model of no association (Additional file 2). As can be seen from Additional file 2, the type-1 error was well controlled for all the tests.

### GAW17 analysis results

In addition to theoretical power comparison and population genetics simulations we also used the GAW17 data set to compare our test with other methods. The GAW17 data set was designed to mimic a real exome sequencing study of a complex disease. Full description of the method used to generate the GAW17 data can be found in Almasy et al. [25]. Briefly, the whole-exome sequencing data from 1000 Genomes Project (http://www.1000genomes.org) was the basis for simulation of 200 replicates of dichotomous phenotype and 200 replicates of 3 quantitative traits (endophenotypes) in 697 unrelated individuals from six populations (Chinese, Japanese, Yoruba, Luhya, Utah residents with Northen and Western European ancestry – CEPH, and Tuscan). Causal variants were chosen to be common and rare non-synonymous SNPs concentrated in genes from specific pathways. Also, dichotomous phenotype and quantitative traits were impacted by covariates such as smoking status, gender and age.

*G*be the genotype matrix of a gene under investigation;

*Q*

_{1},

*Q*

_{2},

*D*– vectors of two quantitative traits and a dichotomous phenotype respectively;

*E*

_{ i }, = 1,2,3 – vectors of age, gender and smoking status respectively;

*R*– matrix of ten principal components obtained from Eigenstrat [27]. First, phenotypes, genotype and covariates were adjusted for population stratification as follows: adjusted genotype $\stackrel{\u2323}{G}=G-R{R}^{T}G$; adjusted phenotypes ${\tilde{Q}}_{1}={Q}_{1}-R{R}^{T}{Q}_{1},{\tilde{Q}}_{2}={Q}_{2}-R{R}^{T}{Q}_{2},\tilde{D}=D-R{R}^{T}\mathit{D}$; adjusted covariates ${\tilde{E}}_{i}={E}_{i}-R{R}^{T}{E}_{i},i=1,2,3$. Second, covariates were regressed out from adjusted phenotypes using the following models:

where *q*_{1},*q*_{2} and *d* are regression residuals. These residuals were tested for an association with adjusted genotype $\tilde{G}$. Statistical significance for each method was assessed using 1000 permutations. The power was calculated as a proportion of phenotype replicates significant at the type-1 error rate of 0.05.

### GAW17 analysis results: comparison with the score test

We considered three partitionings for our method: MAF partitioning (two groups: variants with MAF above and below 1%), functional partitioning (two groups: non-synonymous variants; synonymous and unknown variants), and combined partitioning (four groups defined by MAF and functionality). To assess the empirical type-1 error rate of our method and those of the score test we ran the analysis with randomly permuted residuals *q*_{1},*q*_{2} and *d* from (1). Additional file 3 shows the empirical type-1 error rates for *Q*_{1} and *Q*_{2} traits (Panel 1) and dichotomous phenotype (Panel 2). It should be noted that the estimate of type-1 error rate is distributed as an observed probability of success for a binomial random variable with the sample size of 200 (number of phenotype replicates) and the probability of success 0.05 (theoretical type-1 error rate). The double-sided 99% confidence interval for the estimate of type-1 error rate is 0.015–0.095. As can be seen from Additional file 3, the type-1 error was well controlled.

*Q*

_{1}and

*Q*

_{2}(genes from

*ARNT*to

*VEGFA*were tested on association with

*Q*

_{1}, genes from

*BCHE*to

*VWF*– with

*Q*

_{2}). Panel 2 of Figure 3 depicts the results of the analysis for the dichotomous trait. As can be seen, the score test was significantly more powerful for

*KDR*,

*BCHE*and

*SOS2*genes (dichotomous phenotype), whereas for at least one partitioning the proposed method was substantially more powerful for

*ARNT*,

*ELAVL4*,

*HIF1A*genes (

*Q*

_{1}trait);

*VNN1*gene (

*Q*

_{2}trait);

*FLT1*and

*PIK3C3*genes (dichotomous phenotype). Table 1 shows our suggested reasons for the difference in performance between the score test and our proposed method for the genes listed above. As can be seen, for all the genes for which our method outperformed the score test, some of the considered partitionings contained a group consisting of only associated variants. This is likely to have resulted in our method achieving higher power compared with those of the score test. It should be noted that for

*ELAVL4*gene the major association signal is borne by common variants, although according to the GAW17 phenotype model this gene contains only rare causal variants. To confirm this hypothesis, we performed an association analysis of

*ELAVL4*common SNPs with

*Q*

_{1}trait using the score test. The power to identify an association was 79% after adjusting for population stratification and confounders. For the genes

*KDR*,

*BCHE*and

*SOS2*we did not observe any clear separation of associated variants using any of the considered partitionings.

**Suggested reasons for the difference in power between the score test and our approach for some genes**

Genes | Partitioning | Suggested reason for the difference in performance |
---|---|---|

Genes for which our method outperformed the score test | ||

| MAF and functionality | All common non-synonymous SNPs are causal. |

| MAF | Association of the three common non-causal SNPs with |

| MAF | The only common SNP is causal. |

| MAF | The only common SNP is causal. |

| MAF and functionality | All common non-synonymous SNPs are causal. |

| MAF and functionality | All common non-synonymous SNPs are causal. |

Genes for which the score test outperformed our method | ||

| - | No clear separation of associated variants from neutral ones using any of the considered partitionings. |

### GAW17 analysis results: comparison with other tests

We contrasted the performance of our method (MAF partitioning) with those of WSCS [22], VT [18], SSUw [23] and SKAT-O with linear kernel and beta weights [24]. Also, we included some of the published results obtained by the participants of the GAW17 workshop: the performance of Multivariate Distance Matrix Regression (MDMR) and Mantel tests on *Q*_{2} causal genes [28], the performance of aggregated U-test (AggregateU) and CMC method (QuTie) on *Q*_{1} causal genes [29]. It should be noted that the adjustment for covariates and population stratification for SKAT-O test was done via the function “SKAT_Null_Model” of the R (http://cran.r-project.org) package “SKAT”. Also, in our implementation of the WSCS method rare variant weights were proportional to the absolute value of correlation between those rare variants and phenotype, since the original weights described by Dai et al. [22] were not applicable due to the adjusted phenotype being quantitative. Additional file 4 shows the empirical type-1 error estimates for WSCS, VT, SSUw and SKAT-O tests. Given that the 99% confidence interval for the empirical estimate of type-1 error rate is 0.015–0.095 as described previously, there was no evidence for type-1 error inflation.

Panel 3 of Figure 3 depicts the analysis results for *Q*_{1} causal genes. As can be seen, our method was among the top three most powerful approaches for *ANRT*, *ELAVL4* and *HIF1A* genes. Panel 1 of Additional file 5 shows the results for *Q*_{2} causal genes. Our method was the top performer for *VNN3* gene, and was among the top three performing approaches for *LPL* and *VNN1* genes. Panel 2 of Additional file 5 depicts the results of an association analysis of all causal genes with dichotomous phenotype. As can be seen, SKAT-O achieved the most notable power gains for *PIK3C3* and *PTK2B* genes. This emphasizes that SKAT-O may significantly outperform other tests under some phenotype models. However, this method also may significantly underperform other tests for some phenotype models, for example, *ELAVL4* gene with *Q*_{1} trait and *VNN1* gene with *Q*_{2} trait. Our proposed method was among the top three performing methods for *SOS2*, *PTK2B*, *PRKCA* genes and some other genes for which the power of all the methods was low.

## Discussion

In this article we have described a methodology that incorporates prior information into a region-based score test with the purpose of improving power to identify an association. Prior information, such as observed MAF, functional annotation, predicted deleteriousness of non-synonymous variants, may be used to partition variants within a region of interest. Then, this partitioning is utilized to construct a test statistic whose distribution under the null hypothesis has lower degrees of freedom compared with those of the score test. Based on the theoretical power comparison, population genetics simulations and GAW17 sequencing data analysis, we have shown that under some scenarios our method may perform as well as or outperform other methods.

Our suggested partitioning is splitting by functionality and if rare variants are present – by MAF with an arbitrary threshold, e.g., 1%. One of the major justifications for considering MAF in a partitioning design is that MAF may distinguish between different evolutionary forces acting on causal variants. Evolutionary theory predicts that variants that confer susceptibility to a disease which in turn reduces fitness are expected to have low MAF due to purifying selection. Empirically, using whole-exome sequencing data, it was found that non-synonymous substitutions are more significantly skewed towards low frequencies compared with synonymous variants. This finding “almost certainly reflects the operation of purifying selection” [30] acting on many genes across genome. Thus, if a causal gene is under strong purifying selection incorporating MAF into partitioning design is likely to be beneficial. On the other hand, a causal variant could have risen to higher frequency due to other forces such as balancing selection, mutation-selection balance, antagonistic pleiotropy, etc. [31]. Thus, for example, if a causal variant has been under a strong balancing selection it is likely to be common; and incorporating MAF into partitioning design may lead to power improvement. Partitioning by functionality may be beneficial for gene-based analysis in cases when an association signal comes from one or several functional groups of variants. For example, if highly deleterious non-synonymous variants within exons of a gene are causal, then partitioning by functionality is likely to improve power. Although the misclassification rate for prediction tools may be high (e.g., PolyPhen-2 achieved 92% power to detect truly damaging variants at 20% type-1 error rate over HumDiv data [32]), our method may still benefit from grouping variants by functional significance, since this is an effective way to give more emphasis on variants that are more likely to be causal [33]. The benefit of using functional information was demonstrated in several simulations and candidate gene sequencing studies [18, 34, 35].

There are a few limitations of the proposed methodology. First, it is unknown in advance which prior information is relevant for a given genomic region. Prior information that does not help to uncover groups of associated variants is likely to have negative impact on statistical power. Second, the test statistic (3) is, in general, not invariant with respect to the ordering of SNPs. This can be seen, for example, when the covariance matrix *V* is invariant with respect to permutation of elements of the score vector *U* (e.g., all the cross-SNP covariances are the same, and diagonal variances are equal). So, for any SNP ordering the Cholesky decomposition *A* is the same; hence, the test statistic is, in general, dependent on ordering. To clarify the ambiguity the ordering of SNPs according to a position on a chromosome may be assumed.

## Conclusions

A novel statistical approach that incorporates prior information in a region-based score test with the purpose of improving power has been proposed. Theoretical power comparison, population genetics simulations and the results of the GAW17 data set analysis showed that under some scenarios our method may perform as well as or outperform other methods.

## Methods

*G*= {

*g*

_{ nl },

*n*= 1, …,

*N*,

*l*= 1, …,

*L*} coded as minor allele counts, where

*n*and

*l*are indices for individuals and variants respectively;

*N*× 1 vector of genotypes for the

*l*th variant

*g*

_{ l }= {

*g*

_{ nl },

*n*= 1, …,

*N*}; mean of genotype for the

*l*th variant ${\overline{g}}_{l}$; phenotype vector

*Y*= {

*y*

_{ n },

*n*= 1, …,

*N*}, mean of phenotype $\overline{Y}$. Consider the generalized linear model

*g*(

*Ey*) =

*b*

_{0}+

*Gb*, where

*b*= {

*b*

_{1}, …,

*b*

_{ L }} is a vector of regression coefficients, and

*g*is a monotone link function. The score test statistic used to test an association of phenotype with genotype is as follows [36]:

where $U={\left\{{\displaystyle \sum _{n=1}^{N}}\left({y}_{n}-\overline{Y}\right)\left({g}_{\mathit{nl}}-{\overline{g}}_{l}\right)\right\}}_{l=1}^{L}$ is the vector of scores, $V=\mathit{Cov}\left(G\right){\displaystyle \sum _{n=1}^{N}}{\left({y}_{n}-\overline{Y}\right)}^{2}$ is *L* × *L* the score covariance matrix assumed to be non-singular, and $\mathit{Cov}\left(G\right)={\left\{\mathit{Cov}\left({g}_{l},{g}_{l\text{'}}\right)\right\}}_{l,l\text{'}=1}^{L}$ is the *L* × *L* genotype covariance matrix. Under the null hypothesis (none of the variants is associated with phenotype) *T*_{0} asymptotically follows chi-squared distribution with *rank*(*V*) degrees of freedom (d.f.). Under the alternative hypothesis (at least one variant is associated with phenotype) the asymptotic distribution of (2) can be approximated by a non-central chi-squared distribution.

Following is the description of our proposed method. First, let us transform the coordinates of score vector *U* to be asymptotically independent under the null hypothesis. If we denote *C* = (*A*^{
T
})^{−1}, where matrix *A* is a Cholesky decomposition of *V* (*V* = *A*^{
T
}*A*), the vector *S* = *CU*, under the null hypothesis, is asymptotically distributed as a standard multivariate normal random vector (since *Cov*(*CU*) = *CCov*(*U*)*C*^{
T
} = (*A*^{
T
})^{− 1}*VA*^{− 1} = (*A*^{
T
})^{− 1}(*A*^{
T
}*A*)*A*^{− 1} = *I*). It should be noted that under the alternative hypothesis S is approximately distributed as a multivariate normal random vector with nonzero mean and unit covariance matrix under the assumption of *V* being a reasonable approximation for the covariance matrix of *U*[37]. In general, any other decomposition of the covariance matrix *V* of the form *V* = *A*^{
T
}*A* can be used. We apply Cholesky decomposition because it is fast to compute even for big covariance matrices.

*L*SNPs within a region into

*K*disjoint groups

*G*

_{ k },

*k*= 1, …,

*K*of size

*L*

_{ k },

*k*= 1, …,

*K*. This partitioning is done using prior information, for example: by observed MAF (below and above some arbitrary frequency threshold); by functional annotation (non-synonymous and synonymous for exon sequencing studies; exonic, intronic, 3′UTR, 5′UTR and intergenic for gene-based studies); by functional significance for non-synonymous SNPS (benign, probably and possibly damaging from SIFT or PolyPhen output) etc. For each group let us define ${t}_{k}={\displaystyle \sum _{l\in {G}_{k}}}{s}_{l}^{2},k=1,\dots ,K$, where

*s*

_{ l },

*l*= 1, …,

*L*is the

*l*th coordinate of the vector

*S*. It should be noted that partitioning based on prior to

*S*, since

*S*= (

*A*

^{ T })

^{−1}

*U*is the vector

*U*in a new basis, which is the set of column vectors of the matrix

*A*

^{ T }(old basis is a standard basis). Since the vector

*S*is multivariate normal with unit covariance matrix,

*t*

_{ k },

*k*= 1, …,

*K*are asymptotically independent. Under the null hypothesis

*t*

_{ k }asymptotically follows central chi-squared distribution with

*L*

_{ k }degrees of freedom, whereas under the alternative hypothesis at least one of the

*t*

_{ k },

*k*= 1, …,

*K*is distributed as a non-central chi-squared random variable. Let us denote as

*P*

_{ l }and

*P*

_{ l }

^{−1}cumulative distribution function (CDF) of central chi-squared random variable with

*l*d.f. and its inverse respectively. Group statistics

*H*

_{ k }are defined as follows:

*H*

_{ k }follows a central chi-squared distribution with 1 d.f. Finally, the test statistic of our proposed method is:

Under the null hypothesis *T*_{1} is distributed as a chi-squared random variable with *K* d.f. Large value of *T*_{1} indicates the deviation from the null hypothesis. Transformation (3) is used to decrease the degrees of freedom of the final test, as some of the groups *G*_{
k
}, *k* = 1, …, *K* may contain only neutral variants. If *k*th group does not contain associated SNPs, group *G*_{
k
} contributes only 1 d.f. to the final test, whereas it adds *L*_{
k
} d.f. to the score test. Thus, under “informative” partitioning our proposed method may gain power compared with the score test.

There are few notes that should be taken into account when applying our method. First, the theoretical approximation for distribution of *t*_{
k
} may not hold under moderate sample sizes. Hence, in all our simulations and real data application we used the empirical CDF of *t*_{
k
}, denoted as *F*_{
k
}, obtained via 1000 permutations under the null hypothesis. Instead of ${P}_{{L}_{k}}\left({t}_{k}\right)$ in (3) we calculated a Gaussian kernel CDF estimate *F*_{
k
}(*t*_{
k
}) with a multi-stage plug-in bandwidth of Polansky and Baker [38]. R (http://cran.r-project.org) package ‘kerdiest’ contains all the necessary algorithms. Second, the covariance matrix *V* may happen to be computationally or exactly singular when, for example, considering a region with high LD between common SNPs. In general, to avoid singularity issues we apply Monroe-Penrose pseudoinverse in (2) instead of *V*^{−1}. This pseudoinverse is uniquely defined and equals the standard inverse matrix when *V* is non-singular. From the same considerations instead of usual Cholesky factoring we used generalized Cholesky decomposition, which is well defined for square symmetric positive semi-definite matrices. If *V* is non-singular, the generalized Cholesky decomposition equals the usual Cholesky factoring. Also, it should be noted that in general our test statistic is not invariant with respect to the ordering of variants within a region. To clarify the ambiguity we assume the ordering of SNPs according to a position on a chromosome (see the “Discussion” section).

### Theoretical power calculations

*r*(the connection between

*r*and effect size is provided in the Additional files 6 and 7). Also, we will use the notations

*P*

_{l,r}and

*P*

_{l,r}

^{−1}for the CDF of non-central chi-squared random variable with

*l*d.f. and NCP

*r*and its inverse respectively. The power of the score test with type-1 error rate

*α*is:

*q*

_{1−α,L}is 1 −

*α*quantile of the chi-squared distribution with

*L*d.f. Let us assume that all the causal SNPs are uncorrelated with other SNPs within a region, and that they are in one of the

*K*groups (without loss of generality, let it be the first group

*k*= 1). Then, the power of the proposed test is:

*K*− 1 d.f., because all associated SNPs are in the first group. The probability in (6) can be computed using the convolution of two CDFs as follows:

Under the alternative hypothesis non-centrality parameter of *T*_{0} and those of *t*_{1} are equal, since both statistics include all the associated SNPs within a region. Thus, the distribution of *H*_{1} is ${P}_{1}^{-1}\left({P}_{{L}_{1}}\left({\chi}_{{L}_{1},r}^{2}\right)\right)$, and the integrand in the equation (7) can be calculated as $P\left({H}_{1}<{q}_{1-\alpha ,K}-x\right)={P}_{{L}_{1},r}\left({P}_{{L}_{1}}^{-1}\left({P}_{1}\left({q}_{1-\alpha ,K}-x\right)\right)\right)$. This allows us to compute the theoretical power of our method.

### Population genetics simulations

Boyko et al. [39] found a simple two-epoch expansion model to be one of the best-fit models for population genetics simulations of African-American genotype. Also, the authors found strong evidence of selective effects acting on new amino acid replacing mutations and inferred the distribution of those selective effects. The scaled population selection coefficient (defined as a selection coefficient multiplied by twice the effective population size) was assumed to follow a negative gamma distribution with the following parameters: shape 0.184 and scale 8200. Mutation rate was set at 1.8 × 10^{−8} per nucleotide per generation. The selective disadvantage was additive. Using the forward simulator SFS_CODE (http://sfscode.sourceforge.net) with the parameters described above, we generated 100 haplotype pools for a 3 kb coding genomic region. Each haplotype pool contained 4000 haplotypes. In our simulations we considered only non-synonymous variants. To generate a data replicate we first selected a haplotype pool at random. Within that pool we sampled a pair of haplotypes at random and added those haplotypes to form a multi-site genotype of an “individual”. Dichotomous phenotype was assigned based on this multi-site genotype using a linear logistic model through which we controlled the odds ratios of causal variants. The probability of a disease conditional on the wild type genotype was set at 1% for all phenotype models.

We considered four phenotype scenarios. For the first model called “Rare” randomly chosen 50% of rare variants (defined as those with MAF<1%) within a haplotype pool were assigned to be causal with uniform odds ratio of 3. For the “Low Frequency” scenario one randomly chosen low frequency SNP (MAF between 1% and 5% in a haplotype pool) was causal with odds ratio of 2.5. If there was no SNP with MAF between 1% and 5% in a haplotype pool, we selected a SNP with the lowest MAF above 5%. For the “Common” scenario one common SNP with MAF>5% in a haplotype pool was causal and had the odds ratio of 1.5. Finally, the “Interaction” scenario models the hypothesized interaction of common and rare variants in *RET* gene associated with Hirschsprung’s disease [40, 41]. The simulation framework for this scenario was previously described by Liu and Leal [42]. Briefly, 50% of rare variants were assigned to be causal. Each causal rare minor allele increased the odds of a disease by 6 times if and only if it was present on the same haplotype as a minor allele of a common SNP randomly chosen beforehand.

Sample sizes were the following: 500 cases and 500 controls for “Rare”, “Low frequency” and “Common” scenarios; 1000 cases and 1000 controls for “Interaction” model. In total 1000 data replicates were generated for each scenario. Power was estimated as a proportion of data replicates significant at a fixed type-1 error of 0.05. For all the statistical tests 1000 permutations were applied to estimate a significance level.

## Declarations

### Acknowledgements

We would like to thank the GAW17 workshop organizers for their permission to use their data in our research. Preparation of the Genetic Analysis Workshop 17 Simulated Exome Data Set was supported by the GAW grant, R01 GM031575, and in part by NIH R01 MH059490. The workshop used sequencing data from the 1000 Genomes Project (http://www.1000genomes.org).

**Funding**

This work was supported by the Agency for Science, Technology and Research (A*STAR, Singapore). The first author is a recipient of the Singapore International Graduate Award.

## Authors’ Affiliations

## References

- Maher B: Personal genomes: the case of the missing heritability. Nature. 2008, 456: 18-21.View ArticlePubMedGoogle Scholar
- Park J-H, Wacholder S, Gail MH, Peters U, Jacobs KB, Chanock SJ, Chatterjee N: Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010, 42 (7): 570-575. 10.1038/ng.610.View ArticlePubMed CentralPubMedGoogle Scholar
- Schork NJ, Murray SS, Frazer KA, Topol EJ: Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev. 2009, 19 (3): 212-219. 10.1016/j.gde.2009.04.010.View ArticlePubMed CentralPubMedGoogle Scholar
- Ahituv N, Kavaslar N, Schackwitz W, Ustaszewska A, Martin J, Hébert S, Doelle H, Ersoy B, Kryukov G, Schmidt S, et al: Medical sequencing at the extremes of human body mass. Am J Hum Genet. 2007, 80 (4): 779-791. 10.1086/513471.View ArticlePubMed CentralPubMedGoogle Scholar
- Azzopardi D, Dallosso AR, Eliason K, Hendrickson BC, Jones N, Rawstorne E, Colley J, Moskvina V, Frye C, Sampson JR, et al: Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. Cancer Res. 2008, 68 (2): 358-363. 10.1158/0008-5472.CAN-07-5733.View ArticlePubMedGoogle Scholar
- Bowes J, Lawrence R, Eyre S, Panoutsopoulou K, Orozco G, Elliott K, Ke X, Morris A, Thomson W, Worthington J, et al: Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis. Hum Genet. 2010, 128 (6): 627-633. 10.1007/s00439-010-0889-1.View ArticlePubMed CentralPubMedGoogle Scholar
- Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, Grundy SM, Hobbs HH: Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A. 2006, 103 (6): 1810-1815. 10.1073/pnas.0508483103.View ArticlePubMed CentralPubMedGoogle Scholar
- Haller G, Torgerson DG, Ober C, Thompson EE: Sequencing the IL4 locus in African Americans implicates rare noncoding variants in asthma susceptibility. J Allergy Clin Immunol. 2009, 124 (6): 1204-1209. 10.1016/j.jaci.2009.09.013. e1209View ArticlePubMed CentralPubMedGoogle Scholar
- Li B, Leal M: Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet. 2008, 83: 311-321. 10.1016/j.ajhg.2008.06.024.View ArticlePubMed CentralPubMedGoogle Scholar
- Madsen B, Browning S: A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet. 2009, 5: e1000384-10.1371/journal.pgen.1000384.View ArticlePubMed CentralPubMedGoogle Scholar
- Bansal V, Libiger O, Torkamani A, Shork JN: Statistical analysis strategies for association studies involving rare variants. Nat Rev Genet. 2011, 11: 773-785.View ArticleGoogle Scholar
- Han F, Pan W: A data-adaptive sum test for disease association with multiple common or rare variants. Hum Hered. 2010, 70 (1): 42-54. 10.1159/000288704.View ArticlePubMed CentralPubMedGoogle Scholar
- Li Y, Byrnes AE, Li M: To identify associations with rare variants, just WHaIT: weighted haplotype and imputation-based tests. Am J Hum Genet. 2010, 87 (5): 728-735. 10.1016/j.ajhg.2010.10.014.View ArticlePubMed CentralPubMedGoogle Scholar
- Neale BM, Rivas MA, Voight BF, Altshuler D, Devlin B, Orho-Melander M, Kathiresan S, Purcell SM, Roeder K, Daly MJ: Testing for an unusual distribution of rare variants. PLoS Genet. 2011, 7 (3): e1001322-10.1371/journal.pgen.1001322.View ArticlePubMed CentralPubMedGoogle Scholar
- Quintana MA, Berstein JL, Thomas DC, Conti DV: Incorporating model uncertainty in detecting rare variants: the Bayesian risk index. Genet Epidemiol. 2011, 35 (7): 638-649. 10.1002/gepi.20613.View ArticlePubMed CentralPubMedGoogle Scholar
- Luedtke A, Powers S, Petersen A, Sitarik A, Bekmetjev A, Tintle N: Evaluating methods for the analysis of rare variants in sequence data. BMC Proc. 2011, 5 (Suppl 9): S119-10.1186/1753-6561-5-S9-S119.View ArticlePubMed CentralPubMedGoogle Scholar
- Chen G: Enhancing the discovery of rare disease variants through hierarchical modeling. BMC Proc. 2011, 5 (Suppl 9): S16-10.1186/1753-6561-5-S9-S16.View ArticlePubMed CentralPubMedGoogle Scholar
- Price AL, Kryukov GV, de Bakker PIW, Purcell SM, Staples J, Wei L-J, Sunyaev SR: Pooled association tests for rare variants in exon-resequencing studies. Am J Hum Genet. 2010, 86 (6): 832-838. 10.1016/j.ajhg.2010.04.005.View ArticlePubMed CentralPubMedGoogle Scholar
- Teng M, Wang Y, Wang G, Jung J, Edenberg H, Sanford J, Liu Y: Prioritizing single-nucleotide variations that potentially regulate alternative splicing. BMC Proc. 2011, 5 (Suppl 9): S40-10.1186/1753-6561-5-S9-S40.View ArticlePubMed CentralPubMedGoogle Scholar
- Wei P, Liu X, Fu Y-X: Incorporating predicted functions of nonsynonymous variants into gene-based analysis of exome sequencing data: a comparative study. BMC Proc. 2011, 5 (Suppl 9): S20-10.1186/1753-6561-5-S9-S20.View ArticlePubMed CentralPubMedGoogle Scholar
- Namkung J, Raska P, Kang J, Liu Y, Lu Q, Zhu X: Analysis of exome sequences with and without incorporating prior biological knowledge. Genet Epidemiol. 2011, 35 (S1): S48-S55. 10.1002/gepi.20649.View ArticlePubMed CentralPubMedGoogle Scholar
- Dai Y, Jiang R, Dong J: Weighted selective collapsing strategy for detecting rare and common variants in genetic association study. BMC Genet. 2012, 13 (1): 7-View ArticlePubMed CentralPubMedGoogle Scholar
- Basu S, Pan W: Comparison of statistical tests for disease association with rare variants. Genet Epidemiol. 2011, 35 (7): 606-619. 10.1002/gepi.20609.View ArticlePubMed CentralPubMedGoogle Scholar
- Lee S, Wu MC, Lin X: Optimal tests for rare variant effects in sequencing association studies. Biostatistics. 2012, 13 (4): 762-775. 10.1093/biostatistics/kxs014.View ArticlePubMed CentralPubMedGoogle Scholar
- Almasy L, Dyer T, Peralta J, Kent J, Charlesworth J, Curran J, Blangero J: Genetic Analysis Workshop 17 mini-exome simulation. BMC Proc. 2011, 5 (Suppl 9): S2-10.1186/1753-6561-5-S9-S2.View ArticlePubMed CentralPubMedGoogle Scholar
- Jiang R, Dong J: Detecting rare functional variants using a wavelet-based test on quantitative and qualitative traits. BMC Proc. 2011, 5 (Suppl 9): S70-10.1186/1753-6561-5-S9-S70.View ArticlePubMed CentralPubMedGoogle Scholar
- Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006, 38 (8): 904-909. 10.1038/ng1847.View ArticlePubMedGoogle Scholar
- Chung D, Zhang Q, Kraja A, Borecki I, Province M: Distance-based phenotypic association analysis of DNA sequence data. BMC Proc. 2011, 5 (Suppl 9): S54-10.1186/1753-6561-5-S9-S54.View ArticlePubMed CentralPubMedGoogle Scholar
- Li M, Fu W, Lu Q: An aggregating U-Test for a genetic association study of quantitative traits. BMC Proc. 2011, 5 (Suppl 9): S23-10.1186/1753-6561-5-S9-S23.View ArticlePubMed CentralPubMedGoogle Scholar
- Gibson G: Rare and common variants: twenty arguments. Nat Rev Genet. 2012, 13 (2): 135-145. 10.1038/nrg3118.View ArticlePubMed CentralPubMedGoogle Scholar
- Kryukov GV, Pennacchio LA, Sunyaev SR: Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet. 2007, 80 (4): 727-739. 10.1086/513473.View ArticlePubMed CentralPubMedGoogle Scholar
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Meth. 2010, 7 (4): 248-249. 10.1038/nmeth0410-248.View ArticleGoogle Scholar
- Kiezun A, Garimella K, Do R, Stitziel NO, Neale BM, McLaren PJ, Gupta N, Sklar P, Sullivan PF, Moran JL, et al: Exome sequencing and the genetic basis of complex traits. Nat Genet. 2012, 44 (6): 623-630. 10.1038/ng.2303.View ArticlePubMed CentralPubMedGoogle Scholar
- Sul JH, Han B, He D, Eskin E: An optimal weighted aggregated association test for identification of rare variants involved in common diseases. Genetics. 2011, 188 (1): 181-188. 10.1534/genetics.110.125070.View ArticlePubMed CentralPubMedGoogle Scholar
- Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang S-C, Forey N, et al: Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 2009, 85 (4): 427-446. 10.1016/j.ajhg.2009.08.018.View ArticlePubMed CentralPubMedGoogle Scholar
- Sha Q, Zhang Z, Zhang S: An improved score test for genetic association studies. Genet Epidemiol. 2011, 35 (5): 350-359. 10.1002/gepi.20583.View ArticlePubMedGoogle Scholar
- Self SG, Mauritsen RH: Power/sample size calculations for generalized linear models. Biometrics. 1988, 44 (1): 79-86. 10.2307/2531897.View ArticleGoogle Scholar
- Polansky AM, Baker ER: Multistage plug—in bandwidth selection for kernel distribution function estimates. J Statist Comput Simul. 2000, 65 (1–4): 63-80.View ArticleGoogle Scholar
- Boyko AR, Williamson SH, Indap AR, Degenhardt JD, Hernandez RD, Lohmueller KE, Adams MD, Schmidt S, Sninsky JJ, Sunyaev SR, et al: Assessing the evolutionary impact of amino acid mutations in the human genome. PLoS Genet. 2008, 4 (5): e1000083-10.1371/journal.pgen.1000083.View ArticlePubMed CentralPubMedGoogle Scholar
- Fitze G, Appelt H, König IR, Görgens H, Stein U, Walther W, Gossen M, Schreiber M, Ziegler A, Roesner D, et al: Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR). Hum Mol Genet. 2003, 12 (24): 3207-3214. 10.1093/hmg/ddg354.View ArticlePubMedGoogle Scholar
- Fitze G, Schierz M, Kuhlisch E, Schreiber M, Ziegler A, Roesner D, Schackert HK: Novel intronic polymorphisms in the RET proto-oncogene and their association with Hirschsprung disease. Hum Mutat. 2003, 22 (2): 177-177.View ArticlePubMedGoogle Scholar
- Liu DJ, Leal SM: A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions. PLoS Genet. 2010, 6 (10): e1001156-10.1371/journal.pgen.1001156.View ArticlePubMed CentralPubMedGoogle Scholar

## Copyright

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.